CiMaas validates new methodology for feeder cells expansion
Feeder cells play a critical role in enabling robust proliferation and activation of NK cells during ex vivo manufacturing. A […]
Feeder cells play a critical role in enabling robust proliferation and activation of NK cells during ex vivo manufacturing. A […]
CiMaas receives a new grant from LIOF to further explore the recently developed and patented feeder cell technology. A GMP
As of today, CiMaas is located at the Schleperweg 36, in Maastricht (NL). In this facility we continue our work
Thanks to an investment from 819 Evergreen Fund I, we are pleased to be able to continue working on our
The Committee for Advanced Therapies (CAT) from the European Medicine Agency (EMA) has classified the NK cell technology developed by CiMaas as somatic cell
Upon rigorous analysis, our research has demonstrated that this innovative feeder cell approach results in an enhanced proliferation rate for
CiMaas has filed a new patent application on a new method for the feeder cell preparation in support of its
CiMaas BV announces that it has created a GMP grade master cell bank of the F012 feeder cell line to
CiMaas’ leading product to fight cancer is Natural Killer (NK) cells. These cells kill tumor cells directly as has been
After several years of collaboration, Professor Dr Dean Lee has become a formal member of the scientific advisory board of CiMaas